Met Life Investment Management, LLC Century Therapeutics, Inc. Transaction History

Met Life Investment Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jun 14, 2023	BUY	$4.84 - $11.58 $58,888 - $140,893	12,167 New	12,167 $62,000
Q3 2022 Jun 14, 2023	BUY	$8.57 - $13.1 $104,271 - $159,387	12,167 New	12,167 $120,000
Q2 2022 Jun 20, 2023	BUY	$7.96 - $12.43 $96,849 - $151,235	12,167 New	12,167 $102,000
Q1 2022 May 10, 2024	BUY	$11.62 - $15.92 $141,380 - $193,698	12,167 New	12,167 $153,000
Q1 2022 Jun 20, 2023	BUY	$11.62 - $15.92 $141,380 - $193,698	12,167 New	12,167 $153,000
Q1 2022 Mar 22, 2023	BUY	$11.62 - $15.92 $83,989 - $115,069	7,228 Added 146.35%	12,167 $153,000
Q1 2022 May 12, 2022	BUY	$11.62 - $15.92 $141,380 - $193,698	12,167 New	12,167 $153,000
Q4 2021 Feb 15, 2022	SELL	$13.93 - $23.62 $68,800 - $116,659	-4,939 Closed	0 $0
Q3 2021 May 17, 2024	BUY	$20.8 - $31.93 $102,731 - $157,702	4,939 New	4,939 $124,000
Q3 2021 Jun 21, 2023	BUY	$20.8 - $31.93 $102,731 - $157,702	4,939 New	4,939 $124,000
Q3 2021 Mar 22, 2023	SELL	$20.8 - $31.93 $150,342 - $230,790	-7,228 Reduced 59.41%	4,939 $124,000
Q3 2021 Nov 15, 2021	BUY	$20.8 - $31.93 $102,731 - $157,702	4,939 New	4,939 $124,000

36.9M

8.7K

10.2K

Ticker IPSC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,881,800
Market Cap $74.2M
Description
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 fo...

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Met Life Investment Management, LLC with notifications on news.